We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CHRS market cap is 228.3M. The company's latest EPS is USD -2.1362 and P/E is -0.97.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 45.42M | 45.35M | 32.44M | 58.72M | 74.57M |
| Operating Income | -80.45M | -51.49M | -67.75M | -34.54M | -32.01M |
| Net Income | -86.65M | -58.87M | -75.73M | -42.87M | -39.64M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 356.07M | 475.82M | 326.55M | 211.04M | 257.24M |
| Operating Income | 107.77M | 156.32M | -263.86M | -256.88M | -203.2M |
| Net Income | 89.83M | 132.24M | -287.1M | -291.75M | -237.89M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 550.91M | 480.85M | 402.43M | 469.59M | 583.78M |
| Total Liabilities | 648.04M | 618.27M | 598.93M | 644.36M | 717.38M |
| Total Equity | -97.13M | -137.42M | -196.51M | -174.76M | -133.6M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 408.93M | 841.65M | 679.33M | 480.85M | 629.6M |
| Total Liabilities | 303.71M | 560.68M | 581.61M | 618.27M | 823.03M |
| Total Equity | 105.21M | 280.97M | 97.73M | -137.42M | -193.43M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -141.17M | -241.12M | -68.73M | -107.65M | -161.95M |
| Investing | -36.95M | -166.85M | 17.53M | 58.89M | 109.44M |
| Financing | 47.73M | 54.33M | 3.8M | 58.13M | 69.23M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 28.36M | 154.15M | -37.43M | -241.12M | -174.88M |
| Investing | -12.73M | -14.4M | -138.41M | -166.85M | 144.64M |
| Financing | 89.37M | 223.95M | 51.88M | 54.33M | 69.6M |
| Market Cap | 228.3M |
| Price to Earnings Ratio | -0.97 |
| Price to Sales Ratio | 0.9 |
| Price to Cash Ratio | 2.24 |
| Price to Book Ratio | -1.19 |
| Dividend Yield | - |
| Shares Outstanding | 111.36M |
| Average Volume (1 week) | 1.13M |
| Average Volume (1 Month) | 1.63M |
| 52 Week Change | -72.63% |
| 52 Week High | 8.22 |
| 52 Week Low | 1.4301 |
| Spread (Intraday) | 0.06 (2.91%) |
| Company Name | Coherus BioSciences Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.coherus.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
